Platelet Dysfunction Clinical Trial
Official title:
Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial
This randomized controled open label clinical trial is to evaluate the effect of Cyproheptadine on the clinical course of patients presenting a severe SARS-COV 2 pneumonia.
Observational and biochemical studies have identified an interesting pathway in the pathophysiology of certain clinical-biological characteristics of COVID-19, linked to an excess of serotonin. We hypothesize that the antagonism of the action of serotonin could improve the clinical course of patients most severely affected by COVID-19. One such antagonist of serotonin with a long track record of safety and tolerability is cyproheptadine. Cyproheptadine acts as an antagonist of 5-hydroxytryptamine (5HT=serotonin) receptor subtype 2 as well as histamine-1 receptor. Many of the potent effects of serotonin on lung vascular tone, respiratory rate, and systemic vascular beds are mediated by 5-HT receptor subtype 2. Investigators will randomize approximately 200 participants, aged 18 and older, who have tested positive for COVID-19 and who will be hospitalized at Santa Cabrini Hospital in Montreal, Quebec, Canada, presenting a severe form of covid-pneumonia-19 requiring supplemental oxygen. Study eligibility of all participants will be assessed first. Once a participant is confirmed eligible and consented, they will participate in the study. Participants will be randomly assigned (1: 1) to either take cyproheptadine 8 mg by mouth three times a day for 5 days and receive standard care or receive standard care alone. The dose will be adjusted according to the glomerular filtration rate. On D1, D3, D5, D7 and D10 since randomization, participant's vital signs (including SpO2, respiratory rate, FiO2 or oxygen flow, heart rate, blood pressure and temperature), blood creatinine, bilirubin, CRP, LDH, Dimers and platelets the count will be evaluated. Any adverse event will be assessed daily and documented. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04554901 -
The Effect of Cocoa on Platelet Function Profiles in Patients
|
N/A | |
Completed |
NCT03621020 -
Clinical Performance Evaluation of T-TAS 01 PL Chip
|
||
Completed |
NCT03667066 -
clOpidogrel "resIstaNce" in a Selected Population of Patients at a Tertiary Cardiovascular Center in Trinidad
|
||
Recruiting |
NCT05588011 -
Influence of Oxygenator Selection on Platelet Function and Rotational Thromboelastometry Following Cardiopulmonary Bypass
|
N/A | |
Completed |
NCT01454427 -
Influence of Anesthesia Drugs on Impedance Aggregometry
|
N/A | |
Completed |
NCT03188705 -
CES1 Carriers in the PAPI Study
|
Phase 4 | |
Recruiting |
NCT03583229 -
Coronary Artery Disease After Heart Transplantation
|
N/A | |
Recruiting |
NCT05730114 -
Monitoring Antiplatelet Drugs in Cardiac Arrest Patients
|
||
Completed |
NCT03182946 -
Correcting Platelet Dysfunction After Traumatic Brain Injury
|
||
Completed |
NCT05033236 -
Platelets and Complement Activation in Coronary Artery Bypass Graft Surgery (CABG)
|
||
Recruiting |
NCT04419948 -
Oleocanthal Rich Olive Oil Acute Effects on Hyperglycemia and Platelet Activation in T2DM
|
N/A | |
Completed |
NCT04400760 -
The Effect of Dapagliflozin on Platelet Function testinG Profiles in Diabetic PatiEnts.
|
Phase 2/Phase 3 | |
Completed |
NCT03458351 -
RIPC and Platelet Activation on Platelet Activation During Cardiopulmonary Bypass
|
N/A | |
Completed |
NCT02368730 -
Documentation of the Efficacy of Desmopressin Within the Context of Surgical Procedures
|
N/A | |
Recruiting |
NCT06405516 -
Platelet Function After Cardiac Surgery.
|
N/A | |
Not yet recruiting |
NCT04876573 -
Pilot Study for Cyproheptadine in Hospitalized Patient for COVID-19
|
Phase 2 | |
Completed |
NCT04734028 -
PTRG-DES Consortium
|
||
Completed |
NCT01382134 -
Effect of Aspirin, Hemodilution and Desmopressin on Platelet Dysfunction
|
N/A | |
Completed |
NCT03028064 -
Point of Care Testing of Platelet Function in Patients With Acute Upper Gastrointestinal Bleeding
|
||
Completed |
NCT05237492 -
The Influence of Tramadol on Platelet Function
|
Phase 4 |